STAGE IV LUNG CANCER AJCC V8

This early-phase study tests a new drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially bladder cancer. The main goals are to find the safest dose and understand side effects. About 7…

This study tests a combination of three drugs (docetaxel, ramucirumab, and pembrolizumab) in 30 people with advanced non-small cell lung cancer that worsened after standard chemotherapy and immunotherapy. The goal is to see if this triple therapy is safe and works better than cur…

This early-phase study tests a new combination of two drugs, minnelide and osimertinib, for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). The main goal is to find the safest dose and see how the body responds. Only 8 participants…

This study tested whether adding a second drug (bevacizumab) to the standard targeted therapy (osimertinib) helps control lung cancer that has spread to the brain. It involved 5 adults with a specific gene mutation (EGFR) whose cancer had not been treated with similar drugs befor…

This early-stage trial tests whether adding necitumumab to osimertinib is safe and tolerable for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous targeted therapy. About 138 participants will receive the combination to find the best dos…

This early-phase study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer that has spread or come back. The goal is to find the safest dose of the targeted drug ensartinib when given with standard chemotherapy (carboplatin, pemetrexed) a…

This study tests a vaccine called CIMAvax combined with immunotherapy drugs (nivolumab or pembrolizumab) in people with advanced non-small cell lung cancer or head/neck cancer that has spread. The goal is to find the best dose and see if the combination helps control tumor growth…

This study tests a new drug called pevonedistat combined with standard chemotherapy (carboplatin and paclitaxel) in people with advanced non-small cell lung cancer that has not responded to immunotherapy. The goal is to see if this combination can shrink tumors or slow cancer gro…

This study is for people with advanced non-small cell lung cancer that has come back or spread. It tests a combination of two drugs: trametinib, which blocks cancer cell growth, and pembrolizumab, which helps the immune system attack cancer. The goal is to see if this combination…

This early-phase trial tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread to the brain or other areas. The goal is to find the safest dose and see if the combination can shrink tumors or slow the diseas…

This study tests whether a cancer drug called atezolizumab can be given safely at home to people with non-small cell lung cancer. Instead of going to a clinic, patients receive the injection under the skin from a nurse while using telemedicine. The goal is to see if this home-bas…

This study tests a new drug (aurora kinase inhibitor) combined with a standard targeted therapy (osimertinib) for people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest dose and see if the combination can better control tumor growth. About 32 …

This study looks at whether adding radiation therapy to standard immunotherapy (with or without chemotherapy) can help people with advanced non-small cell lung cancer that lacks the PD-L1 marker. About 427 adults with stage IIIB, IIIC, or IV disease will be randomly assigned to r…

This early trial tests whether adding surgery or radiation to the targeted drug brigatinib can better control advanced ALK-positive non-small cell lung cancer. About 35 people whose cancer has spread or returned will receive both treatments. The main goal is to check safety and s…

This early-phase trial tests the safety and best dose of sonidegib combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have spread. The goal is to see if this drug pair can shrink tumors or slow their growth. About 36 adults with cancers like m…

This early-phase study is for people with a specific kind of advanced lung cancer (ALK-positive non-small cell lung cancer) that has gotten worse despite prior ALK-targeted therapy. Researchers are testing a combination of two drugs—brigatinib and bevacizumab—to see what dose is …

This study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer that responded to initial chemotherapy. The goal is to find the safest dose and see if the combo helps keep can…

This early-phase study tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 participants with…

This phase 3 trial studies the best way to use immunotherapy (pembrolizumab) and chemotherapy for advanced non-squamous non-small cell lung cancer. About 600 participants receive either immunotherapy alone first, then chemo with or without immunotherapy later, or a combination of…

This study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their cancer growing. About 173 adults with stage IIIB or IV non-small cell lung cancer that has a specific EGFR mutatio…

This study tests a DNA vaccine called STEMVAC in people with stage IV non-small cell lung cancer. The vaccine helps the immune system recognize and attack cancer cells. It is given alongside standard maintenance therapy. The goal is to see if it can shrink tumors and improve outc…

This study is for people with advanced squamous non-small cell lung cancer that has spread. It tests a new drug called berzosertib added to standard chemotherapy and immunotherapy. The goal is to find the safest dose and see if the combination helps keep the cancer from growing l…

This study tests whether the drug cabozantinib, alone or combined with the immunotherapy nivolumab, works better than standard chemotherapy for people with advanced non-squamous non-small cell lung cancer that has come back after prior treatment. The trial involves 117 adults wit…

This early-phase study tests a new drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR, which helps some cancers grow. The main goal…

This early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses immune cells from donated umbilical cord blood that are genetically modified to better recognize and attack cance…

This study compares two treatments for lung tumors: microwave ablation (using heat to kill cancer cells) and surgical wedge resection (removing a small piece of lung). It includes people with early or advanced lung cancer, sarcoma, or colorectal cancer that has spread to the lung…

This study tests a drug called AMG 510 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation). The drug is designed to block the cancer's growth signal. About 116 participants will receive the treatment to see if it shrinks tumors and how safe…

This study tests whether adding local treatments like surgery or radiation to a two-drug immunotherapy regimen helps people with stage IV non-small cell lung cancer live longer. About 339 participants will receive either immunotherapy alone or immunotherapy plus local therapy. Th…

This study tests whether a combination of two drugs (ramucirumab and pembrolizumab) works better than standard chemotherapy for people with advanced or returning non-small cell lung cancer who have already tried immunotherapy. About 838 participants will be randomly assigned to o…

This study tests a new treatment combination for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment yet. It combines a PARP inhibitor (olaparib), an immunotherapy drug (durvalumab), standard chemotherapy (carboplatin and etoposide), and radiati…

This study tests a new combination of two drugs, osimertinib and telaglenastat, in people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The goal is to find the safest dose and see how well the drugs work together to stop cancer cells from growin…

This study tests whether combining two drugs—atezolizumab (an immunotherapy that helps the immune system attack cancer) and cobimetinib (a targeted therapy that blocks cancer growth signals)—can shrink tumors or slow disease in people with advanced non-small cell lung cancer that…

This early-stage trial tests a combination of all-trans retinoic acid (ATRA), a drug made from vitamin A, and atezolizumab, an immunotherapy, in 18 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests a drug called selpercatinib (LOXO-292) in people with a specific type of advanced or recurrent non-small cell lung cancer that has a RET gene fusion. The drug works by blocking enzymes that help cancer cells grow. About 124 participants will receive the treatment…

This study looks at whether a drug called anamorelin can help improve appetite and stop weight loss in people with advanced non-small cell lung cancer who have lost their appetite and weight. About 25 participants will take either the drug or a placebo and share their experiences…

This early-phase trial tests a drug called berzosertib combined with whole brain radiation for people with lung cancer that has spread to the brain. The main goal is to find the safest dose and check for side effects. About 15 adults with non-small cell, small cell, or neuroendoc…

This study tests an online program designed to improve social well-being and emotional support for women being treated for lung cancer. About 70 women with stage I to IV non-small cell lung cancer will take part. The program uses mindfulness and emotional processing techniques to…

This study looks at whether using a precise, targeted form of radiation (stereotactic radiosurgery) instead of whole-brain radiation can help preserve brain function in people with small cell lung cancer that has spread to the brain. About 55 participants with up to 10 brain tumo…

This study looks at whether giving a single, precise dose of radiation after lung cancer surgery is safe and causes fewer side effects than the usual weeks-long radiation. About 50 adults with non-small cell lung cancer who had surgery but still have cancer cells at the edge of t…

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with fears about the future. About 42 participants will try the program to see if it is practical and helpful in medical centers and clinics. The goal is to learn if this ap…

This study looks at whether regularly measuring the amount of paclitaxel (a chemotherapy drug) in the blood can help doctors give the right dose to kill cancer while limiting nerve damage. About 22 adults with various solid tumors (like lung, breast, or ovarian cancer) will have …

This study looks at whether watching a short video can help people with metastatic cancer better understand tumor genomic testing. About 243 adults with advanced breast, lung, or other solid tumors will watch the video and answer questions before and after. The goal is to see if …

This study tests a decision aid designed for people with non-small cell lung cancer. The tool helps patients and doctors talk together about treatment options, risks, and what matters most to the patient. About 98 adults with lung cancer will use the tool to see if it improves th…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…